Healthcare provider profile · identity verified

John C Westerbeck, MD

Internal Medicine · MASSILLON, OH · NPI 1619974037

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	369	142
Lisinopril	Lisinopril	181	65
Levothyroxine Sodium	Levothyroxine Sodium	173	60
Amlodipine Besylate	Amlodipine Besylate	162	64
Escitalopram Oxalate	Escitalopram Oxalate	155	52
Metoprolol Succinate	Metoprolol Succinate	131	55
Omeprazole	Omeprazole	121	50
Metformin Hcl	Metformin Hcl	114	44
Losartan Potassium	Losartan Potassium	111	35
Trazodone Hcl	Trazodone Hcl	110	38
Tamsulosin Hcl	Tamsulosin Hcl	103	45
Rosuvastatin Calcium	Rosuvastatin Calcium	88	41
Carvedilol	Carvedilol	81	28
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	81	35
Simvastatin	Simvastatin	81	28
Eliquis	Apixaban	80	23
Alendronate Sodium	Alendronate Sodium	77	25
Gabapentin	Gabapentin	69	27
Pantoprazole Sodium	Pantoprazole Sodium	67	26
Glimepiride	Glimepiride	64	27
Valsartan	Valsartan	63	24
Allopurinol	Allopurinol	57	23
Furosemide	Furosemide	57	20
Naproxen	Naproxen	57	21
Donepezil Hcl	Donepezil Hcl	53	18
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	48	19
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	45	18
Albuterol Sulfate Hfa	Albuterol Sulfate	44	18
Clopidogrel	Clopidogrel Bisulfate	44	15
Famotidine	Famotidine	44	21
Citalopram Hbr	Citalopram Hydrobromide	43	14
Jardiance	Empagliflozin	41	17
Fluticasone Propionate	Fluticasone Propionate	40	23
Hydrochlorothiazide	Hydrochlorothiazide	39	22
Tizanidine Hcl	Tizanidine Hcl	39	20
Buspirone Hcl	Buspirone Hcl	38	12
Duloxetine Hcl	Duloxetine Hcl	38	12
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	37	11
Ozempic	Semaglutide	35	suppressed
Warfarin Sodium	Warfarin Sodium	33	15
Potassium Chloride	Potassium Chloride	32	12
Pravastatin Sodium	Pravastatin Sodium	30	suppressed
Spironolactone	Spironolactone	30	14
Xarelto	Rivaroxaban	30	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	29	suppressed
Montelukast Sodium	Montelukast Sodium	29	12
Metformin Hcl Er	Metformin Hcl	28	13
Pioglitazone Hcl	Pioglitazone Hcl	28	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	28	suppressed
Clonidine Hcl	Clonidine Hcl	27	suppressed
Sertraline Hcl	Sertraline Hcl	26	11
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	26	13
Ezetimibe	Ezetimibe	25	suppressed
Ibandronate Sodium	Ibandronate Sodium	23	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	23	suppressed
Colchicine	Colchicine	22	suppressed
Mirtazapine	Mirtazapine	21	suppressed
Symbicort	Budesonide/Formoterol Fumarate	21	suppressed
Tramadol Hcl	Tramadol Hcl	21	11
Finasteride	Finasteride	20	suppressed
Glipizide	Glipizide	20	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	20	suppressed
Bupropion Hcl Sr	Bupropion Hcl	19	suppressed
Atenolol	Atenolol	18	suppressed
Doxepin Hcl	Doxepin Hcl	18	suppressed
Levetiracetam	Levetiracetam	18	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	18	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	18	suppressed
Synthroid	Levothyroxine Sodium	17	suppressed
Terbinafine Hcl	Terbinafine Hcl	17	11
Celecoxib	Celecoxib	16	suppressed
Irbesartan	Irbesartan	16	suppressed
Nystatin	Nystatin	15	suppressed
Ramipril	Ramipril	15	suppressed
Lovastatin	Lovastatin	14	suppressed
Memantine Hcl	Memantine Hcl	14	suppressed
Mounjaro	Tirzepatide	14	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	13	suppressed
Divalproex Sodium	Divalproex Sodium	13	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	13	13
Liothyronine Sodium	Liothyronine Sodium	12	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	11	suppressed
Pregabalin	Pregabalin	11	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error